文献速递糖尿病

血管紧张素转换酶与2型糖尿病风险:一项孟德尔随机化研究

ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study.
PubMed 文献 · Diabetes Care · 2020-02-04

本研究采用两样本孟德尔随机化分析,利用ORIGIN试验中17个与ACE血清浓度相关的独立遗传变异及DIAGRAM联盟18项研究数据,并在UK Biobank 341872名参与者中验证。结果提示遗传决定的较低ACE浓度与2型糖尿病风险降低相关,且经血压标准化后ACE遗传风险评分对应的风险降低幅度大于RCT荟萃分析所估计的效应。

要点

  • 遗传决定的较低ACE浓度与2型糖尿病风险降低相关(OR 0.92,95%CI 0.89-0.95)。
  • 该结果在UK Biobank中重复验证(OR 0.97,95%CI 0.96-0.99)。
  • 经血压标准化后,ACE遗传风险评分对应的2型糖尿病风险降低幅度大于RCT荟萃分析估计值。

核心结论

  • 结果支持ACE抑制剂对2型糖尿病风险具有因果保护效应,并可能指导临床实践中的治疗决策。

研究设计与样本

  • 两样本孟德尔随机化分析,纳入ORIGIN试验4147名参与者中17个与ACE血清浓度相关的独立遗传变异,并从DIAGRAM联盟18项研究估计其对2型糖尿病风险的效应。
  • 在UK Biobank 341872名参与者(含16320例2型糖尿病患者)中检验与较低ACE浓度相关的遗传风险评分与2型糖尿病患病率的关联。
  • 将孟德尔随机化估计值经血压变化标准化后,与ACE抑制剂对比安慰剂的随机对照试验荟萃分析(n=31200)估计值进行比较。

主要发现

  • 遗传决定的较低ACE浓度与较低的2型糖尿病风险相关(每标准差OR 0.92,95%CI 0.89-0.95;P=1.79×10-7)。
  • 该结果在UK Biobank中重复验证(每标准差OR 0.97,95%CI 0.96-0.99;P=8.73×10-4)。
  • 经标准化后,ACE遗传风险评分与平均动脉压每降低2.4 mmHg对应的2型糖尿病风险降低相关(OR 0.19,95%CI 0.07-0.51),而RCT荟萃分析对应估计值为OR 0.76(95%CI 0.60-0.97),两者差异P=0.007。

临床怎么用

  • 作者认为这些结果支持ACE抑制剂对2型糖尿病风险的因果保护效应,并可能指导临床实践中的治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether ACE inhibitors reduce the risk of type 2 diabetes using a Mendelian randomization (MR) approach. RESEARCH DESIGN AND METHODS: A two-sample MR analysis included 17 independent genetic variants associated with ACE serum concentration in 4,147 participants from the Outcome Reduction with Initial Glargine INtervention (ORIGIN) (clinical trial reg. no. NCT00069784) trial, and their effects on type 2 diabetes risk were estimated from 18 studies of the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium. A genetic risk score (GRS) underpinning lower ACE concentration was then tested for association with type 2 diabetes prevalence in 341,872 participants, including 16,320 with type 2 diabetes, from the UK Biobank. MR estimates were compared after standardization for blood pressure change, with the estimate obtained from a randomized controlled trial (RCT) meta-analysis of ACE inhibitors versus placebo (n = 31,200). RESULTS: Genetically lower ACE concentrations were associated with a lower risk of type 2 diabetes (odds ratio [OR] per SD 0.92 [95% CI 0.89-0.95]; P = 1.79 × 10-7). This result was replicated in the UK Biobank (OR per SD 0.97 [0.96-0.99]; P = 8.73 × 10-4). After standardization, the ACE GRS was associated with a larger decrease in type 2 diabetes risk per 2.4-mmHg lower mean arterial pressure (MAP) compared with that obtained from an RCT meta-analysis (OR per 2.4-mmHg lower MAP 0.19 [0.07-0.51] vs. 0.76 [0.60-0.97], respectively; P = 0.007 for difference). CONCLUSIONS: These results support the causal protective effect of ACE inhibitors on type 2 diabetes risk and may guide therapeutic decision making in clinical practice.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Pigeyre M, Sjaarda J, Chong M, et al. ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes Care. 2020. PMID: 32019855. doi:10.2337/dc19-1973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。